Medtide Inc. Honored with 2026 Forbes China Industry Development Leading Enterprise Award

Shanghai, China--(Newsfile Corp. - May 15, 2026) - On March 18, 2026, Frost & Sullivan and Forbes China Group jointly hosted the 2026 Forbes China Pioneer Innovators in Industry Development Selection Gala Banquet at the Bulgari Hotel in Shanghai. The awards, co-initiated by Forbes China Group and Frost & Sullivan, feature one main category—the "2026 Forbes China Industry Development Pioneer Innovators"—and three sub-categories: "2026 Forbes China Industry Development Leading Enterprises," "2026 Forbes China Industry Development Innovative Brands," and "2026 Forbes China Industry Development Emerging Analysts." A total of 86 individuals and enterprises received honors. Leveraging its prominent position and comprehensive capabilities in the CRDMO sector, Medtide Inc. (hereinafter "Medtide" or "the Company") was awarded the title of "2026 Forbes China Industry Development Leading Enterprise."

Medtide (HKEX: 03880.HK) is a global CRDMO company specializing in peptides and oligonucleotides. Originally founded as Chinese Peptide Company in 2001, the company has accumulated over 25 years of industry experience and evolved into an integrated service platform covering the entire drug development lifecycle—from early discovery and clinical research to commercial manufacturing. Supported by its commercial production base in Hangzhou, China, and ongoing capacity expansion in the United States, Medtide has established delivery capabilities that meet the standards of major global regulatory authorities, serving pharmaceutical and biotechnology clients worldwide.

I. A Pioneer in the Global Peptide CRDMO Sector: 25 Years of Expertise Forging a Robust Technical Moat

As a pioneer in the global peptide CRDMO sector, Medtide has dedicated over 25 years to peptide synthesis and related services, building end-to-end capabilities spanning early drug discovery, preclinical research, clinical development, and commercial manufacturing. In the field of peptide synthesis, the company has established a formidable technical moat, achieving an average success rate of over 99.95% in new molecule synthesis.

In terms of its technology platforms, the company has developed seven proprietary systems: OmniPeptSynth™, PeptiConjuX™, PeptiNucLide LinkTech™, GreenSynth Innovations™, Impurity Screening™, GreenPepisolate™, and DisulfideDetect™. Among these, the PeptiConjuX™ platform focuses on peptide-drug conjugate development, integrating advanced modification technologies such as on-resin cyclization, N-methylation, glycosylation, and various forms of PEGylation. The PeptiNucLide LinkTech™ platform specializes in radionuclide conjugate drug synthesis, representing the company's core in-house solution in the peptide-radionuclide conjugation space.

Schreibe Deinen Kommentar